Literature DB >> 28404639

Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.

George N Ioannou1,2, Savitha Subramanian3, Alan Chait3, W Geoffrey Haigh4, Matthew M Yeh5, Geoffrey C Farrell6, Sum P Lee2, Christopher Savard4,2.   

Abstract

We recently reported that cholesterol crystals form in hepatocyte lipid droplets (LDs) in human and experimental nonalcoholic steatohepatitis. Herein, we assigned WT C57BL/6J mice to a high-fat (15%) diet for 6 months, supplemented with 0%, 0.25%, 0.5%, 0.75%, or 1% dietary cholesterol. Increasing dietary cholesterol led to cholesterol loading of the liver, but not of adipose tissue, resulting in fibrosing steatohepatitis at a dietary cholesterol concentration of ≥0.5%, whereas mice on lower-cholesterol diets developed only simple steatosis. Hepatic cholesterol crystals and crown-like structures also developed at a dietary cholesterol concentration ≥0.5%. Crown-like structures consisted of activated Kupffer cells (KCs) staining positive for NLRP3 and activated caspase 1, which surrounded and processed cholesterol crystal-containing remnant LDs of dead hepatocytes. The KCs processed LDs at the center of crown-like structures in the extracellular space by lysosomal enzymes, ultimately transforming into lipid-laden foam cells. When HepG2 cells were exposed to LDL cholesterol, they developed cholesterol crystals in LD membranes, which caused activation of THP1 cells (macrophages) grown in coculture; upregulation of TNF-alpha, NLRP3, and interleukin 1beta (IL1β) mRNA; and secretion of IL-1beta. In conclusion, cholesterol crystals form on the LD membrane of hepatocytes and cause activation and cholesterol loading of KCs that surround and process these LDs by lysosomal enzymes.

Entities:  

Keywords:  cholesterol crystal; fatty liver; lipotoxicity; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2017        PMID: 28404639      PMCID: PMC5456359          DOI: 10.1194/jlr.M072454

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  49 in total

1.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.

Authors:  Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

2.  Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

Authors:  Temitope Foster; Matthew J Budoff; Sammy Saab; Naser Ahmadi; Craig Gordon; Alan D Guerci
Journal:  Am J Gastroenterol       Date:  2010-09-14       Impact factor: 10.864

3.  Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice.

Authors:  Savitha Subramanian; Leela Goodspeed; Shari Wang; Jinkyu Kim; Lixia Zeng; George N Ioannou; W Geoffrey Haigh; Matthew M Yeh; Kris V Kowdley; Kevin D O'Brien; Subramaniam Pennathur; Alan Chait
Journal:  J Lipid Res       Date:  2011-06-20       Impact factor: 5.922

4.  A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

Authors:  Austin Nelson; Dawn M Torres; Ana E Morgan; Christopher Fincke; Stephen A Harrison
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

Review 5.  Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader
Journal:  Prog Lipid Res       Date:  2012-12-01       Impact factor: 16.195

6.  The Nalp3 inflammasome is essential for the development of silicosis.

Authors:  Suzanne L Cassel; Stephanie C Eisenbarth; Shankar S Iyer; Jeffrey J Sadler; Oscar R Colegio; Linda A Tephly; A Brent Carter; Paul B Rothman; Richard A Flavell; Fayyaz S Sutterwala
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-24       Impact factor: 11.205

7.  Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

Authors:  Hae-Ki Min; Ashwani Kapoor; Michael Fuchs; Faridoddin Mirshahi; Huiping Zhou; James Maher; John Kellum; Russell Warnick; Melissa J Contos; Arun J Sanyal
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

8.  Type and amount of dietary fat affect relative concentration of cholesterol in blood and other tissues of rats.

Authors:  K D Wiggers; M J Richard; J W Stewart; N L Jacobson; P J Berger
Journal:  Atherosclerosis       Date:  1977-05       Impact factor: 5.162

9.  Adipocyte death, adipose tissue remodeling, and obesity complications.

Authors:  Katherine J Strissel; Zlatina Stancheva; Hideaki Miyoshi; James W Perfield; Jason DeFuria; Zoe Jick; Andrew S Greenberg; Martin S Obin
Journal:  Diabetes       Date:  2007-09-11       Impact factor: 9.461

10.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

View more
  41 in total

1.  Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis.

Authors:  Yvonne Baumer; Qimin Ng; Gregory E Sanda; Amit K Dey; Heather L Teague; Alexander V Sorokin; Pradeep K Dagur; Joanna I Silverman; Charlotte L Harrington; Justin A Rodante; Shawn M Rose; Nevin J Varghese; Agastya D Belur; Aditya Goyal; Joel M Gelfand; Danielle A Springer; Christopher Ke Bleck; Crystal L Thomas; Zu-Xi Yu; Mårten Cg Winge; Howard S Kruth; M Peter Marinkovich; Aditya A Joshi; Martin P Playford; Nehal N Mehta
Journal:  JCI Insight       Date:  2018-01-11

2.  Ultramorphological analysis of plaque advancement and cholesterol crystal formation in Ldlr knockout mouse atherosclerosis.

Authors:  Yvonne Baumer; Sara McCurdy; Xueting Jin; Tina M Weatherby; Amit K Dey; Nehal N Mehta; Jonathan K Yap; Howard S Kruth; William A Boisvert
Journal:  Atherosclerosis       Date:  2019-06-12       Impact factor: 5.162

Review 3.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

Review 4.  Targeting fatty acid metabolism for fibrotic disorders.

Authors:  Seonghwan Hwang; Ki Wung Chung
Journal:  Arch Pharm Res       Date:  2021-10-18       Impact factor: 4.946

Review 5.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

6.  Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?

Authors:  Joel Grunhut; Wei Wang; Berk Aykut; Inderdeep Gakhal; Alejandro Torres-Hernandez; George Miller
Journal:  Eur Med J Hepatol       Date:  2018-05-31

Review 7.  Lipid mediators of liver injury in nonalcoholic fatty liver disease.

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-01       Impact factor: 4.052

Review 8.  Digestive exophagy: Phagocyte digestion of objects too large for phagocytosis.

Authors:  Frederick R Maxfield; Valeria C Barbosa-Lorenzi; Rajesh K Singh
Journal:  Traffic       Date:  2019-12-02       Impact factor: 6.215

Review 9.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

10.  Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease.

Authors:  Joost Willebrords; Michaël Maes; Isabel Veloso Alves Pereira; Tereza Cristina da Silva; Veronica Mollica Govoni; Valéria Veras Lopes; Sara Crespo Yanguas; Valery I Shestopalov; Marina Sayuri Nogueira; Inar Alves de Castro; Anwar Farhood; Inge Mannaerts; Leo van Grunsven; Jephte Akakpo; Margitta Lebofsky; Hartmut Jaeschke; Bruno Cogliati; Mathieu Vinken
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-12       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.